申淑荣,王兴德,周丽,陈忠,程培,姜利明.丹红注射液联合替格瑞洛治疗急性ST段抬高型心肌梗死的临床研究[J].现代药物与临床,2019,34(5):1313-1317
丹红注射液联合替格瑞洛治疗急性ST段抬高型心肌梗死的临床研究
Clinical study on Danhong Injection combined with ticagrelor in treatment of acute ST segment elevation myocardial infarction
投稿时间:2019-02-18  
DOI:10.7501/j.issn.1674-5515.2019.05.010
中文关键词:  丹红注射液  替格瑞洛片  急性ST段抬高型心肌梗死  心功能  心肌酶  炎性因子
英文关键词:Danhong Injection  Ticagrelor Tablets  acute ST segment elevation myocardial infarction  cardiac function  inflammatory factor
基金项目:上海申康医院发展中心临床科技创新项目(SHDC12016238);上海健康医学院种子基金项目(SFP-18-22-14-017)
作者单位
申淑荣 上海健康医学院附属第六人民医院东院 心内科, 上海 201306 
王兴德 上海健康医学院附属第六人民医院东院 心内科, 上海 201306 
周丽 上海健康医学院附属第六人民医院东院 心内科, 上海 201306 
陈忠 上海健康医学院附属第六人民医院东院 心内科, 上海 201306 
程培 上海健康医学院附属第六人民医院东院 心内科, 上海 201306 
姜利明 上海健康医学院附属第六人民医院东院 心内科, 上海 201306 
摘要点击次数: 121
全文下载次数: 129
中文摘要:
      目的 探讨丹红注射液联合替格瑞洛片治疗急性ST段抬高型心肌梗死的临床疗效。方法 选取2016年3月—2018年3月上海健康医学院附属第六人民医院东院收治的急性ST段抬高型心肌梗死患者200例为研究对象,随机将所有患者分为对照组和治疗组,每组各100例。对照组患者口服替格瑞洛片,1片/次,2次/d。治疗组在对照组治疗的基础上静脉滴注丹红注射液,40 mL溶于5%葡萄糖注射液250 mL中,1次/d。两组均治疗2周。观察两组患者的临床疗效,同时比较两组治疗前后的心功能指标、心肌酶水平和血清炎性因子水平。结果 治疗后,对照组和治疗组的总有效率分别为79.00%、96.00%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组左室射血分数(LVEF)显著升高,左心室舒张末期内径(LVEDD)和左心室收缩末期内径(LVESD)水平显著降低(P<0.05);且治疗后治疗组心功能指标显著优于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者肌钙蛋白I(cTnI)、肌酸激酶(CK)和心肌肌酸激酶同工酶(CK-MB)水平显著降低,同组治疗前后比较差异具有统计学意义(P<0.05);且治疗后治疗组的心肌酶水平明显低于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者白细胞介素-6(IL-6)、血清C反应蛋白(CRP)和肿瘤坏死因子-α(TNF-α)水平均显著降低,同组治疗前后比较差异具有统计学意义(P<0.05);且治疗后治疗组血清炎性因子水平均显著低于对照组,两组比较差异具有统计学意义(P<0.05)。结论 丹红注射液联合替格瑞洛片治疗急性ST段抬高型心肌梗死具有较好的临床疗效,能够改善患者心功能,降低血清炎性因子水平,具有一定的临床推广应用价值。
英文摘要:
      Objective To investigate the clinical effect of Danhong Injection combined with Ticagrelor Tablets in treatment of acute ST segment elevation myocardial infarction. Methods Patients (200 cases) with acute ST segment elevation myocardial infarction in East Hospital of Sixth People's Affiliated to Shanghai University of Medicine & Health Sciences from March 2016 to March 2018 were randomly divided into control and treatment groups, and each group had 100 cases. Patients in the control group were po administered with Ticagrelor Tablets, 1 tablet/time, twice daily. Patients in the treatment group were iv administered with Danhong Injection on the basis of control group, 40 mL added into 5% Glucose Injection 250 mL, once daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacies were evaluated, and the cardiac function indexes, myocardial enzymes levels, and the serum levels of inflammatory factors in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 79.00% and 96.00%, respectively, and there was difference between two groups (P < 0.05). After treatment, LVEF in two groups were significantly increased, but LVEDD and LVESD were decreased, and the difference was statistically significant in the same group (P< 0.05). And cardiac function indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P< 0.05). After treatment, the levels of cTnI, CK, and CK-MB in two groups were significantly decreased, and the difference was statistically significant in the same group (P< 0.05). And the myocardial enzymes levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P< 0.05). After treatment, the levels of IL-6, CRP, and TNF-α in two groups were significantly decreased, and the difference was statistically significant in the same group (P< 0.05). And the inflammatory factors levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P< 0.05). Conclusion Danhong Injection combined with Ticagrelor Tablets has a good clinical effect in treatment of acute ST segment elevation myocardial infarction, can improve the cardiac function of patients', and reduce the serum levels of inflammatory factors, which has a certain clinical application value.
HTML  查看全文  查看/发表评论  下载PDF阅读器
关闭
您是第 6064353 位访客
版权所有 天津中草药杂志社(天津市南开区鞍山西道308号 300193)
联系电话:022-23006823 传真:022-23006823 E_mail:dc@tiprpress.com
津备案:津ICP备13000267号 互联网药品信息服务资格证书编号:(津)-非经营性-2015-0031